vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $196.9M, roughly 1.0× Pacira BioSciences, Inc.). On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 5.1%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $43.5M). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs 8.5%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
COLL vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $196.9M |
| Net Profit | $17.0M | — |
| Gross Margin | 62.5% | 79.5% |
| Operating Margin | 29.6% | 1.2% |
| Net Margin | 8.3% | — |
| Revenue YoY | 12.9% | 5.1% |
| Net Profit YoY | 35.3% | — |
| EPS (diluted) | $0.48 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | $196.9M | ||
| Q3 25 | $209.4M | $179.5M | ||
| Q2 25 | $188.0M | $181.1M | ||
| Q1 25 | $177.8M | $168.9M | ||
| Q4 24 | $181.9M | $187.3M | ||
| Q3 24 | $159.3M | $168.6M | ||
| Q2 24 | $145.3M | $178.0M | ||
| Q1 24 | $144.9M | $167.1M |
| Q4 25 | $17.0M | — | ||
| Q3 25 | $31.5M | $5.4M | ||
| Q2 25 | $12.0M | $-4.8M | ||
| Q1 25 | $2.4M | $4.8M | ||
| Q4 24 | $12.5M | — | ||
| Q3 24 | $9.3M | $-143.5M | ||
| Q2 24 | $19.6M | $18.9M | ||
| Q1 24 | $27.7M | $9.0M |
| Q4 25 | 62.5% | 79.5% | ||
| Q3 25 | 61.7% | 80.9% | ||
| Q2 25 | 57.7% | 77.4% | ||
| Q1 25 | 54.8% | 79.7% | ||
| Q4 24 | 54.0% | 78.7% | ||
| Q3 24 | 60.8% | 76.9% | ||
| Q2 24 | 62.5% | 75.1% | ||
| Q1 24 | 63.1% | 71.6% |
| Q4 25 | 29.6% | 1.2% | ||
| Q3 25 | 29.7% | 3.5% | ||
| Q2 25 | 18.7% | 4.7% | ||
| Q1 25 | 12.2% | 1.2% | ||
| Q4 24 | 20.9% | 13.2% | ||
| Q3 24 | 21.9% | -82.8% | ||
| Q2 24 | 32.7% | 15.9% | ||
| Q1 24 | 34.1% | 7.9% |
| Q4 25 | 8.3% | — | ||
| Q3 25 | 15.0% | 3.0% | ||
| Q2 25 | 6.4% | -2.7% | ||
| Q1 25 | 1.4% | 2.8% | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 5.9% | -85.1% | ||
| Q2 24 | 13.5% | 10.6% | ||
| Q1 24 | 19.1% | 5.4% |
| Q4 25 | $0.48 | $0.05 | ||
| Q3 25 | $0.84 | $0.12 | ||
| Q2 25 | $0.34 | $-0.11 | ||
| Q1 25 | $0.07 | $0.10 | ||
| Q4 24 | $0.36 | $0.38 | ||
| Q3 24 | $0.27 | $-3.11 | ||
| Q2 24 | $0.52 | $0.39 | ||
| Q1 24 | $0.71 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $301.7M | $693.1M |
| Total Assets | $1.7B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | $238.4M | ||
| Q3 25 | $285.9M | $246.3M | ||
| Q2 25 | $222.2M | $445.9M | ||
| Q1 25 | $197.8M | $493.6M | ||
| Q4 24 | $162.8M | $484.6M | ||
| Q3 24 | $120.0M | $453.8M | ||
| Q2 24 | $271.6M | $404.2M | ||
| Q1 24 | $318.0M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $301.7M | $693.1M | ||
| Q3 25 | $274.8M | $727.2M | ||
| Q2 25 | $232.2M | $757.8M | ||
| Q1 25 | $234.4M | $798.5M | ||
| Q4 24 | $228.8M | $778.3M | ||
| Q3 24 | $234.3M | $749.6M | ||
| Q2 24 | $216.6M | $879.3M | ||
| Q1 24 | $222.2M | $892.2M |
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.6B | $1.3B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.7B | $1.6B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.1B | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $43.7M |
| Free Cash FlowOCF − Capex | $122.4M | $43.5M |
| FCF MarginFCF / Revenue | 59.6% | 22.1% |
| Capex IntensityCapex / Revenue | 0.3% | 0.1% |
| Cash ConversionOCF / Net Profit | 7.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | $43.7M | ||
| Q3 25 | $78.4M | $60.8M | ||
| Q2 25 | $72.4M | $12.0M | ||
| Q1 25 | $55.4M | $35.5M | ||
| Q4 24 | $84.6M | $33.1M | ||
| Q3 24 | $-9.0M | $53.9M | ||
| Q2 24 | $67.4M | $53.2M | ||
| Q1 24 | $61.9M | $49.1M |
| Q4 25 | $122.4M | $43.5M | ||
| Q3 25 | $78.3M | $57.0M | ||
| Q2 25 | $72.4M | $9.3M | ||
| Q1 25 | $54.6M | $26.9M | ||
| Q4 24 | $84.1M | $31.0M | ||
| Q3 24 | $-9.2M | $49.8M | ||
| Q2 24 | $67.1M | $51.6M | ||
| Q1 24 | $61.4M | $46.3M |
| Q4 25 | 59.6% | 22.1% | ||
| Q3 25 | 37.4% | 31.7% | ||
| Q2 25 | 38.5% | 5.1% | ||
| Q1 25 | 30.7% | 15.9% | ||
| Q4 24 | 46.2% | 16.6% | ||
| Q3 24 | -5.8% | 29.6% | ||
| Q2 24 | 46.2% | 29.0% | ||
| Q1 24 | 42.3% | 27.7% |
| Q4 25 | 0.3% | 0.1% | ||
| Q3 25 | 0.1% | 2.2% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.4% | 5.1% | ||
| Q4 24 | 0.3% | 1.1% | ||
| Q3 24 | 0.2% | 2.4% | ||
| Q2 24 | 0.2% | 0.9% | ||
| Q1 24 | 0.4% | 1.7% |
| Q4 25 | 7.25× | — | ||
| Q3 25 | 2.49× | 11.20× | ||
| Q2 25 | 6.05× | — | ||
| Q1 25 | 22.92× | 7.37× | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | 2.82× | ||
| Q1 24 | 2.23× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COLL
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
